BRAF and non-small cell lung carcinoma: The concurrent combination of dabrafenib and trametinib plus osimertinib was also attempted in two patients with BRAF V600E NSCLC postprogression to osimertinib, but, due to toxicity, one patient ultimately received a reduced dose of dabrafenib and trametinib.